路易氏體失智症治療市場－全球產業規模、佔有率、趨勢、機會及預測（按分銷管道、藥物類型、地區和競爭格局分類，2021-2031年）

全球路易氏體失智症治療市場預計將從 2025 年的 52.4 億美元成長到 2031 年的 77.2 億美元，複合年成長率為 6.67%。

該市場涵蓋旨在控制由大腦中異常α-突觸核蛋白沉積引起的複雜認知、運動和精神症狀的藥物和非藥物干預措施。推動這一市場成長的關鍵因素是全球老年人口的不斷成長以及由此導致的神經退化性疾病診斷數量的增加，這自然擴大了目標患者群體。此外，診斷生物標記的持續進步提高了早期區分失智症與其他類型失智症的能力，從而能夠制定更及時的治療策略，進一步促進了該領域的成長。

然而，市場擴張的一大障礙是誤診率高，因為其症狀與阿茲海默症和帕金森氏症有顯著重疊。這種診斷上的模糊性常常延誤了適當治療的啟動，並阻礙了特定療法的有效實施。根據阿茲海默症協會2024年的報告顯示，約5%的老年失智症患者僅患有路易體失智症，這一數據凸顯了將這類特定患者群體與更廣泛的失智症患者群體中患有混合性疾病的患者區分開來的複雜性。

市場促進因素

由於迫切需要疾病修正治療（不僅緩解症狀，還能改變潛在病理的治療方法），強大的臨床研發管線和加速的藥物開發工作是市場擴張的關鍵驅動力。製藥公司正在加強研究針對新型作用機制的藥物，例如p38α激酶抑制劑，以解決與路易氏體相關的潛在突觸功能障礙。隨著後期臨床試驗的推進，潛在治療方法正朝著監管部門的核准邁進，為傳統上依賴仿單標示外用藥的患者群體帶來了希望。例如，2024年10月，CervoMed公司宣布其neflamapimod的RewinD-LB IIb期臨床試驗已完成最後一次患者訪視，這標誌著針對該適應症的特異性治療方法開發取得了重要里程碑式的進展。

公共和私人部門對神經系統疾病研究的投入不斷增加，為高風險、高回報的藥物研發計畫提供了必要的資金，進一步鞏固了市場成長。資金的增加支持了大規模的縱向研究和生物標記檢驗，為患者分層和提高臨床試驗成功率奠定了基礎。一個顯著的例子是賓州大學醫學院於2024年9月宣布：美國國家老齡研究所（NIA）津貼1800萬美元，用於研究路易氏體失智症認知衰退的原因和生物標記。鑑於該疾病對醫療保健系統帶來的巨大經濟負擔，這些投資至關重要，它們促使支付方和醫療服務提供者探索有效的治療方法。 2024年1月發表在《英國精神病學雜誌開放版》（BJPsych Open）上的一篇系統性回顧指出，路易氏體失智症（LBD）確診後一年內，平均醫療費用上升至29174美元，凸顯了開發有效臨床解決方案的巨大經濟價值。

市場挑戰

全球路易氏體失智症治療市場成長面臨的主要障礙之一是誤診率高，這是由於其症狀與阿茲海默症和帕金森氏症重疊。這種診斷上的模糊性顯著限制了潛在市場，因為很大一部分患者接受的是其他神經退化性疾病的治療，而非路易氏體失智症的特異性治療。因此，製藥開發商在確定合適的臨床試驗患者群體方面面臨巨大挑戰，從而延緩了標靶療法的核准和商業化進程。無法準確篩選這類患者群體降低了製藥企業的潛在投資回報，阻礙了研發進展，並限制了市場擴張。

這個問題實際上將很大一部分潛在基本客群隱藏起來，使市場參與企業難以觸及。根據路易氏體失智症協會估計，到2024年，美國將有約140萬人患有路易氏體失智症。這項統計數據表明，該疾病的實際盛行率與準確診斷的病例數之間存在嚴重脫節。只要這些患者仍未被識別或被錯誤地歸類到更廣泛的失智症患者群體中，市場就無法充分利用對路易體失智症特異性治療方法的需求，從而直接抑制整體收入潛力。

市場趨勢

將皮膚突觸核蛋白生物標記應用於早期診斷，標誌著市場實踐的重大變革，使該領域從依賴臨床觀察轉向對活體患者進行客觀的病理學檢驗。這一趨勢解決了以往無法在不進行屍檢的情況下確認α-突觸核蛋白沉積的難題，從而能夠更精準地識別臨床試驗和商業性治療中的目標患者。 2024年5月，路易氏體失智症協會報告稱，在由美國國立衛生研究院資助的Synuclein-One研究中，皮膚磷酸化α-突觸核蛋白檢測在臨床診斷為路易氏體失智症的參與者中達到了96%的陽性檢出率。如此高的診斷準確率對於將這些患者與單純的阿茲海默症症患者準確區分開來至關重要，並確保新興的標靶治療能夠惠及目標族群。

同時，市場正果斷轉向緩解疾病α-突觸核蛋白免疫療法，這類療法旨在透過清除有毒蛋白聚集體來阻止神經退化，而不僅僅是控制症狀。研發人員正優先開發主動疫苗策略，訓練病患的免疫系統辨識並清除病理性寡聚物，從而防止其造成不可逆的神經元損傷。為了支持此策略的有效性，AC Immune公司於2024年11月公佈了其II期VacSYn試驗的中期結果，結果顯示，其主動免疫療法候選藥物ACI-7104.056在三次給藥後，與安慰劑相比，平均誘導了16倍更高的抗α-突觸核蛋白抗體水平。這種作用機製表明，該療法有可能延緩疾病進展，並有望徹底改變患者的長期治療模式。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球路易氏體失智症治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依分銷管道（醫院藥局、零售藥局、藥局、網路藥局）
  • 依藥物類型（膽鹼酯酶抑制劑、抗精神病藥物、碳度巴/左旋多巴、抗憂鬱症、苯二氮平類藥物、Modafinil）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美路易氏體失智症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲路易氏體失智症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區路易氏體失智症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲路易氏體失智症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲路易氏體失智症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球路易氏體失智症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• BioArctic AB
• Eisai Co., Ltd
• Sumitomo Pharma Co., Ltd.
• Jazz Pharmaceuticals, Inc.
• Immungenetics ANoven Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc.
• Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Lewy Body Dementia Treatment Market is projected to expand from USD 5.24 Billion in 2025 to USD 7.72 Billion by 2031, reflecting a compound annual growth rate of 6.67%. This market covers pharmacological and non-pharmacological interventions aimed at managing the intricate cognitive, motor, and psychiatric symptoms resulting from abnormal alpha-synuclein deposits in the brain. Key factors propelling this growth include the increasing global population of older adults and the corresponding rise in neurodegenerative diagnoses, which naturally widens the addressable patient base. Furthermore, the sector benefits from continuous advancements in diagnostic biomarkers, which improve the clinical ability to distinguish this condition from other dementias at earlier stages, thereby enabling more timely therapeutic strategies.

Conversely, a significant barrier to market progression is the high frequency of misdiagnosis due to substantial symptomatic overlap with Alzheimer's and Parkinson's diseases. This diagnostic ambiguity often delays appropriate care and restricts the effective deployment of specific treatments. As reported by the Alzheimer's Association in 2024, approximately 5% of older individuals with dementia show evidence of Lewy body dementia alone, a statistic that underscores the complex challenge of isolating this specific patient segment from those with mixed pathologies within the broader dementia population.

Market Driver

A robust clinical pipeline and accelerated drug development efforts serve as a primary catalyst for market expansion, driven by the urgent need for disease-modifying therapies rather than mere symptomatic relief. Pharmaceutical companies are increasingly targeting novel mechanisms of action, such as p38 alpha kinase inhibition, to address the underlying synaptic dysfunction associated with Lewy bodies. This intensification of late-stage clinical trials is bringing potential treatments closer to regulatory approval, offering hope for a patient population that has historically relied on off-label medications. For example, CervoMed reported in October 2024 the completion of the final patient visit in its RewinD-LB Phase 2b clinical trial for neflamapimod, marking a critical milestone in advancing specific therapeutics for this indication.

Market growth is further solidified by increasing public and private investment in neurological research, which provides the necessary capital for high-risk, high-reward discovery programs. Enhanced funding supports large-scale longitudinal studies and biomarker validation, which are essential for stratifying patient populations and improving trial success rates. A notable instance occurred in September 2024, when Penn Medicine announced that the National Institute on Aging awarded an $18 million grant to researchers to investigate the causes of cognitive decline and identify biomarkers in Lewy body diseases. These investments are crucial given the substantial economic burden the disease places on healthcare systems, incentivizing payers and providers to seek effective treatments; a systematic review in BJPsych Open in January 2024 highlighted that average medical costs rose to $29,174 in the first year following an LBD diagnosis, underscoring the immense financial value of developing effective clinical solutions.

Market Challenge

The primary obstacle hindering the growth of the Global Lewy Body Dementia Treatment Market is the high rate of misdiagnosis caused by symptomatic overlaps with Alzheimer's and Parkinson's diseases. This diagnostic ambiguity significantly restricts the addressable market, as a large proportion of patients are treated for other neurodegenerative conditions rather than receiving therapies specifically optimized for Lewy body dementia. Consequently, pharmaceutical developers face substantial hurdles in identifying suitable patient cohorts for clinical trials, which delays the approval and commercialization of targeted treatments. The inability to accurately segregate this patient population reduces the perceived return on investment for drug manufacturers, thereby stalling R&D progress and limiting market expansion.

This issue effectively conceals a massive segment of the potential customer base from market participants. According to the Lewy Body Dementia Association, an estimated 1.4 million individuals in the United States were affected by Lewy body dementia in 2024. This statistic reveals a profound gap between the actual prevalence of the disease and the number of accurately diagnosed cases. As long as these individuals remain unidentified or misclassified within the broader dementia population, the market cannot fully capitalize on the demand for specific Lewy body dementia interventions, directly impeding overall revenue potential.

Market Trends

The integration of cutaneous synuclein biomarkers for early diagnosis represents a critical evolution in market practice, shifting the sector from a reliance on clinical observation toward objective pathological validation in living patients. This trend resolves the historic difficulty of confirming alpha-synuclein deposition without post-mortem analysis, thereby enabling more accurate patient identification for clinical trials and commercial treatment. In May 2024, the Lewy Body Dementia Association reported that the NIH-funded Synuclein-One Study demonstrated that a cutaneous phosphorylated alpha-synuclein test achieved a 96% positive detection rate in participants clinically diagnosed with Lewy body dementia. Such diagnostic precision is essential for accurately segregating these patients from those with pure Alzheimer's disease, ensuring that emerging targeted therapies reach the correct demographic.

Simultaneously, the market is witnessing a decisive shift toward disease-modifying alpha-synuclein immunotherapies, which aim to halt neurodegeneration by clearing toxic protein aggregates rather than merely managing symptoms. Developers are prioritizing active vaccination strategies that train the patient's immune system to recognize and eliminate pathological oligomers before they cause irreversible neuronal damage. Validating this approach, AC Immune announced in November 2024 that interim results from the Phase 2 VacSYn trial showed the active immunotherapy candidate ACI-7104.056 induced anti-alpha-synuclein antibody levels on average 16-fold higher than placebo after three doses. This mechanism suggests a potential for slowing disease progression, fundamentally altering the long-term treatment landscape for affected individuals.

Key Market Players

• BioArctic AB
• Eisai Co., Ltd
• Sumitomo Pharma Co., Ltd.
• Jazz Pharmaceuticals, Inc.
• Immungenetics ANoven Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc.
• Mylan N.V.

Report Scope

In this report, the Global Lewy Body Dementia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lewy Body Dementia Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Lewy Body Dementia Treatment Market, By Drug Type

• Cholinesterase Inhibitors
• Antipsychotic Drugs
• Carbidopa-Levodopa
• Antidepressants
• Benzodiazepine
• Modafinil

Lewy Body Dementia Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lewy Body Dementia Treatment Market.

Available Customizations:

Global Lewy Body Dementia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lewy Body Dementia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)
  • 5.2.2. By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Carbidopa-Levodopa, Antidepressants, Benzodiazepine, Modafinil)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Lewy Body Dementia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Distribution Channel
  • 6.2.2. By Drug Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lewy Body Dementia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Distribution Channel
      • 6.3.1.2.2. By Drug Type
  • 6.3.2. Canada Lewy Body Dementia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Distribution Channel
      • 6.3.2.2.2. By Drug Type
  • 6.3.3. Mexico Lewy Body Dementia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Distribution Channel
      • 6.3.3.2.2. By Drug Type

7. Europe Lewy Body Dementia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Distribution Channel
  • 7.2.2. By Drug Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lewy Body Dementia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Distribution Channel
      • 7.3.1.2.2. By Drug Type
  • 7.3.2. France Lewy Body Dementia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Distribution Channel
      • 7.3.2.2.2. By Drug Type
  • 7.3.3. United Kingdom Lewy Body Dementia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Distribution Channel
      • 7.3.3.2.2. By Drug Type
  • 7.3.4. Italy Lewy Body Dementia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Distribution Channel
      • 7.3.4.2.2. By Drug Type
  • 7.3.5. Spain Lewy Body Dementia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Distribution Channel
      • 7.3.5.2.2. By Drug Type

8. Asia Pacific Lewy Body Dementia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Distribution Channel
  • 8.2.2. By Drug Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lewy Body Dementia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Distribution Channel
      • 8.3.1.2.2. By Drug Type
  • 8.3.2. India Lewy Body Dementia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Distribution Channel
      • 8.3.2.2.2. By Drug Type
  • 8.3.3. Japan Lewy Body Dementia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Distribution Channel
      • 8.3.3.2.2. By Drug Type
  • 8.3.4. South Korea Lewy Body Dementia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Distribution Channel
      • 8.3.4.2.2. By Drug Type
  • 8.3.5. Australia Lewy Body Dementia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Distribution Channel
      • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Lewy Body Dementia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Distribution Channel
  • 9.2.2. By Drug Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lewy Body Dementia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Distribution Channel
      • 9.3.1.2.2. By Drug Type
  • 9.3.2. UAE Lewy Body Dementia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Distribution Channel
      • 9.3.2.2.2. By Drug Type
  • 9.3.3. South Africa Lewy Body Dementia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Distribution Channel
      • 9.3.3.2.2. By Drug Type

10. South America Lewy Body Dementia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Distribution Channel
  • 10.2.2. By Drug Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lewy Body Dementia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Distribution Channel
      • 10.3.1.2.2. By Drug Type
  • 10.3.2. Colombia Lewy Body Dementia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Distribution Channel
      • 10.3.2.2.2. By Drug Type
  • 10.3.3. Argentina Lewy Body Dementia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Distribution Channel
      • 10.3.3.2.2. By Drug Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lewy Body Dementia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BioArctic AB
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eisai Co., Ltd
• 15.3. Sumitomo Pharma Co., Ltd.
• 15.4. Jazz Pharmaceuticals, Inc.
• 15.5. Immungenetics ANoven Pharmaceuticals, Inc.
• 15.6. Eli Lilly and Company
• 15.7. Novartis AG
• 15.8. Pfizer Inc.
• 15.9. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer